Intrahepatic cholangiocarcinoma

Kimberly M. Brown, Abhishek D. Parmar, David A. Geller

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.

Original languageEnglish (US)
Pages (from-to)231-246
Number of pages16
JournalSurgical Oncology Clinics of North America
Volume23
Issue number2
DOIs
StatePublished - Apr 2014

Fingerprint

Cholangiocarcinoma
gemcitabine
Survival
Blood Vessels
Neoplasms
Lymph Nodes
Incidence
Therapeutics

Keywords

  • Bile duct neoplasms
  • Cholangiocarcinoma
  • Intrahepatic bile duct cancer
  • Intrahepatic cholangiocarcinoma
  • Peripheral cholangiocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Intrahepatic cholangiocarcinoma. / Brown, Kimberly M.; Parmar, Abhishek D.; Geller, David A.

In: Surgical Oncology Clinics of North America, Vol. 23, No. 2, 04.2014, p. 231-246.

Research output: Contribution to journalArticle

Brown, KM, Parmar, AD & Geller, DA 2014, 'Intrahepatic cholangiocarcinoma', Surgical Oncology Clinics of North America, vol. 23, no. 2, pp. 231-246. https://doi.org/10.1016/j.soc.2013.10.004
Brown, Kimberly M. ; Parmar, Abhishek D. ; Geller, David A. / Intrahepatic cholangiocarcinoma. In: Surgical Oncology Clinics of North America. 2014 ; Vol. 23, No. 2. pp. 231-246.
@article{ec3dee42456d4abd9333b100d7d08e1f,
title = "Intrahepatic cholangiocarcinoma",
abstract = "Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17{\%} to 44{\%}, with median survivals of 19 to 43months.",
keywords = "Bile duct neoplasms, Cholangiocarcinoma, Intrahepatic bile duct cancer, Intrahepatic cholangiocarcinoma, Peripheral cholangiocarcinoma",
author = "Brown, {Kimberly M.} and Parmar, {Abhishek D.} and Geller, {David A.}",
year = "2014",
month = "4",
doi = "10.1016/j.soc.2013.10.004",
language = "English (US)",
volume = "23",
pages = "231--246",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Intrahepatic cholangiocarcinoma

AU - Brown, Kimberly M.

AU - Parmar, Abhishek D.

AU - Geller, David A.

PY - 2014/4

Y1 - 2014/4

N2 - Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.

AB - Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43months.

KW - Bile duct neoplasms

KW - Cholangiocarcinoma

KW - Intrahepatic bile duct cancer

KW - Intrahepatic cholangiocarcinoma

KW - Peripheral cholangiocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84896739429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896739429&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2013.10.004

DO - 10.1016/j.soc.2013.10.004

M3 - Article

VL - 23

SP - 231

EP - 246

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -